Abstract
Patients with the Zollinger-Ellison syndrome are characterized by islet-cell tumors, striking gastric acid hypersecretion, and peptic ulcer disease. They often experience severe abdominal pain, diarrhea, and gastrointestinal bleeding with potentially life-threatening consequences. It is a rare syndrome caused by nonbeta cell islet-cell tumors (gastrinomas) located in or in proximity to the pancreas. These tumors freely secrete gastrin, a peptide hormone that serves as a powerful stimulant of gastric acid secretion. Exuberant secretion of gastrin from the gastrinomas produces severe gastric acid hypersecretion that often leads to impressive peptic ulcer disease and the constellation of symptoms listed above. We describe a patient presenting with clinical manifestations characteristic of the ZES with strikingly elevated gastric acid secretion, multiple ulcers in the first and second portions of the duodenum and diarrhea, but in absence of islet-cell tumor and/or hypergastrinemia.
Similar content being viewed by others
References
Zollinger RM, Ellison EH. Primary peptic ulceration of the jejunum associated with islet-cell tumors of the pancreas. Ann Surg 1955;142:709–723.
McGuigan JE, Trudeau JL. Immunochemical measurement of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger-Ellison variety. N Engl J Med 1968;78:1308–1313.
Chey WY, Chang TM, Park HJ, et al. A non-gastrin secretagogue in ulcerogenic tumors of the pancreas. Ann Intern Med 1984;101:7–13.
Song Y, Chey WY, Chang T, et al. Mechanism of gastric acid hypersecretion in patients with islet-cell tumor without hypergastrinemia: studies in rats. Gastroenterology 1997;113:1129–1135.
Collen MJ, Sheridan MJ. Definition for idiopathic gastric acid hypersecretion. Dig Dis Sci 1991;36:1371–1376.
Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology 1973;65:140–165.
Devaney CW, Devaney KS, Jaffe BM, et al. Use of calcium and secretin in the diagnosis of gastrinoma (Zollinger-Ellison syndrome). Ann Intern Med 1977;87:680–686.
Mee AS, Ismail S, Bornman PC, et al. Changing concepts in the presentation, diagnosis and management of the Zollinger-Ellison syndrome. Q J M 1983;206:256–267.
Wolfe MM, Jain DK, Edgerton JR, Zollinger-Ellison syndrome associated with persistently normal fasting serum gastrin concentrations. Ann Intern Med 1985;103:215–217.
McGuigan JE, Wolfe MM. The secretin injection test in the diagnosis of gastrinoma. Gastroenterology 1980;79:1324–1331.
Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 1989;111:713–722.
Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994;31:77–156.
Zhuang J, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997;57:4682–4686.
Vogel SB, Wolfe MM, McGuigan JE, et al. Localization and resection of gastrinomas in Zollinger-Ellison syndrome. Ann Surg 1987;205:550–556.
Prinz RA. Localization of gastrinomas. Int J Pancreatol 1996;19:79–91.
Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis: A prospective study. Gastroenterology 1998;95:657–667.
Anderson W, Helman CA, Hirschowitz B. Basophilic leukemia and the hypersecretion of gastric acid and pepsin. Gastroenterology 1998;95:195–198.
Metz DC, Soffer B, Forsmark CE. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. American J Gastroenterol 2003;98(2):301–307.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Desai, A.A., McGuigan, J.E. & Draganov, P. Zollinger-ellison phenotype in the absence of hypergastrinemia and islet-cell tumor. Int J Gastrointest Canc 35, 157–161 (2005). https://doi.org/10.1385/IJGC:35:2:157
Issue Date:
DOI: https://doi.org/10.1385/IJGC:35:2:157